摘要
目的:评价吉非替尼治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法:270例晚期NSCLC患者按用药情况分为吉非替尼组与多西他赛组,两组患者在年龄、性别、病理类型、分期等方面大致平衡。吉非替尼组口服吉非替尼250mg/d;多西他赛组静脉滴注多西他赛75mg/m2,1h,每3周重复给药,直到病变进展或出现不可耐受的不良反应。结果:吉非替尼组与多西他赛组疾病控制率分别为70.9%和57.4%(P<0.05);中位无疾病进展生存时间分别为7.6个月和4.1个月(P<0.05)。因不良反应调整药物剂量,吉非替尼组有4例(2.8%),多西他赛组有21例(16.3%)(P<0.05)。3～4级不良反应发生率,吉非替尼组为12.1%,多西他赛组为41.1%(P<0.05)。结论:吉非替尼治疗晚期NSCLC安全、有效、不良反应轻,患者耐受性较多西他赛更好。
OBJECTIVE： To evalute the efficacy and safety of gefitinib in the treatment of advanced non-small cell lung cancer （NSCLC）. METHODS： 270 advanced NSCLC patients were divided into gefitinib group and docetaxel group. The conditions of patients were similar in terms of age, gender, pathological types and staging. Gefitinib group was given 250 mg/d orally, and docetaxel group was given docctaxel 75 mg/m intravenously tbr 1 h every 3 weeks untile pathological changes made progress or untolerable ADR appeared. RESULTS： The control rate of disease in gefitinib group was 70.9% and in docetaxel group was 57.4% （P〈0.05）. The progression-free survival （PFS） was 7.6 months in gefitinib group and 4.1 months in docetaxel group （P〈0.05）. In gefitinib group, drug dosage of .1 cases were adjusted because of adverse drug reaction （2.8%）, and in docetaxel group there were 21 cases （16.3k） （P〈0.05）. The incidence of 3-4 degree adverse drug reaction was 12.1% in gefitinib group and 41.1% in docetaxel group （P〈0.05）. CONCLUSIONS： Gefitinib is effective and sate tbr advanced NSCLC and causes slight adverse drug reaction. Gcfitinib is more thvorable than docetaxel in the drug tolerance.
出处
《中国药房》
CAS
CSCD
2013年第18期1679-1682,共4页
China Pharmacy
